US EditionPublished • loading... • Updated
Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
Oricell secured $70M to accelerate global trials of solid-tumor CAR-T therapies, advancing lead product Ori-C101 toward a pivotal registrational trial, company said.
- On Jan. 12, 2026, Oricell Therapeutics closed a $70M Series C1 financing co-led by Beijing Medical and Health Care Industry Investment Fund and Qiming Venture Partners in Shanghai and San Francisco.
- Seeking to accelerate clinical progress, Oricell will use the financing to advance global clinical programs and continue R&D and technology development.
- Oricell's clinical data have been presented at ASCO and The Lancet Haematology, supported by three proprietary platforms: Ori•Ab, Ori•Armoring, and OnGo.
- Investors pledged continued backing as proceeds accelerate Oricell's global expansion and clinical development, while CEO Dr. Helen Yang thanked investors and partners for their confidence.
- Meanwhile, Ori‑C101 is entering a registrational pivotal trial after Phase I IIT and Phase I IND studies, while OriC902 advances rapid manufacturing and in vivo CAR‑T exploration.
Insights by Ground AI
22 Articles
22 Articles
PR Newswire+21 Reposted by 21 other sources
Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
/PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the...
·United States
Read Full ArticleCoverage Details
Total News Sources22
Leaning Left2Leaning Right0Center9Last UpdatedBias Distribution82% Center
Bias Distribution
- 82% of the sources are Center
82% Center
L 18%
C 82%
Factuality
To view factuality data please Upgrade to Premium
